JP4328090B2 - 神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用 - Google Patents

神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用 Download PDF

Info

Publication number
JP4328090B2
JP4328090B2 JP2002501464A JP2002501464A JP4328090B2 JP 4328090 B2 JP4328090 B2 JP 4328090B2 JP 2002501464 A JP2002501464 A JP 2002501464A JP 2002501464 A JP2002501464 A JP 2002501464A JP 4328090 B2 JP4328090 B2 JP 4328090B2
Authority
JP
Japan
Prior art keywords
cells
cop
disease
injury
glutamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002501464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507460A5 (cg-RX-API-DMAC7.html
JP2004507460A (ja
Inventor
− シュワルツ、ミカル アイゼンバッハ
ヨールズ、エティ
キプニス、ヨナタン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2004507460A publication Critical patent/JP2004507460A/ja
Publication of JP2004507460A5 publication Critical patent/JP2004507460A5/ja
Application granted granted Critical
Publication of JP4328090B2 publication Critical patent/JP4328090B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002501464A 2000-06-07 2001-01-22 神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用 Expired - Fee Related JP4328090B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20979900P 2000-06-07 2000-06-07
US62021600A 2000-07-20 2000-07-20
PCT/US2001/002118 WO2001093893A2 (en) 2000-06-07 2001-01-22 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Publications (3)

Publication Number Publication Date
JP2004507460A JP2004507460A (ja) 2004-03-11
JP2004507460A5 JP2004507460A5 (cg-RX-API-DMAC7.html) 2006-02-09
JP4328090B2 true JP4328090B2 (ja) 2009-09-09

Family

ID=26904524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002501464A Expired - Fee Related JP4328090B2 (ja) 2000-06-07 2001-01-22 神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用

Country Status (16)

Country Link
US (1) US20020037848A1 (cg-RX-API-DMAC7.html)
EP (1) EP1294390B1 (cg-RX-API-DMAC7.html)
JP (1) JP4328090B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030007397A (cg-RX-API-DMAC7.html)
CN (1) CN100438906C (cg-RX-API-DMAC7.html)
AT (1) ATE314860T1 (cg-RX-API-DMAC7.html)
AU (1) AU783031B2 (cg-RX-API-DMAC7.html)
CA (1) CA2398277C (cg-RX-API-DMAC7.html)
CY (1) CY1105263T1 (cg-RX-API-DMAC7.html)
DE (1) DE60116467T2 (cg-RX-API-DMAC7.html)
DK (1) DK1294390T3 (cg-RX-API-DMAC7.html)
ES (1) ES2256200T3 (cg-RX-API-DMAC7.html)
IL (2) IL150801A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007109A (cg-RX-API-DMAC7.html)
NZ (1) NZ520282A (cg-RX-API-DMAC7.html)
WO (1) WO2001093893A2 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
US7351686B2 (en) * 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
CN1886506B (zh) * 2003-09-29 2012-05-30 中外制药株式会社 在nk细胞中表达的蛋白质
WO2005032482A2 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
CA2546077C (en) * 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da) * 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
CA2565819A1 (en) 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
DK1799703T3 (da) 2004-09-09 2010-04-19 Teva Pharma Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
ES2541780T3 (es) * 2004-11-29 2015-07-24 Yeda Research And Development Co., Ltd. Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン,インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009063459A2 (en) * 2007-11-13 2009-05-22 Yeda Research And Development Co. Ltd Synthetic peptide copolymers for treatment of neurodevelopmental disorders
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
EP4340853A4 (en) * 2021-05-20 2025-05-07 Washington University Neuroprotective compositions and methods
KR20230128606A (ko) * 2022-02-28 2023-09-05 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물
CN121517513A (zh) * 2025-11-20 2026-02-13 西湖大学 一种共聚物多肽及其药物组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
JP2002503658A (ja) * 1998-02-13 2002-02-05 オートイミューン インク COP−1及びTh−2促進性サイトカインを使用した、多発性硬化症の治療

Also Published As

Publication number Publication date
AU783031B2 (en) 2005-09-15
DE60116467T2 (de) 2006-11-02
EP1294390A2 (en) 2003-03-26
EP1294390B1 (en) 2006-01-04
CA2398277A1 (en) 2001-12-13
MXPA02007109A (es) 2002-12-13
DE60116467D1 (de) 2006-03-30
CY1105263T1 (el) 2010-03-03
JP2004507460A (ja) 2004-03-11
IL150801A (en) 2007-10-31
CN1462190A (zh) 2003-12-17
NZ520282A (en) 2004-09-24
CN100438906C (zh) 2008-12-03
AU3451801A (en) 2001-12-17
IL150801A0 (en) 2003-02-12
WO2001093893A3 (en) 2002-04-04
HK1058892A1 (zh) 2004-06-11
ATE314860T1 (de) 2006-02-15
ES2256200T3 (es) 2006-07-16
CA2398277C (en) 2013-09-03
KR20030007397A (ko) 2003-01-23
US20020037848A1 (en) 2002-03-28
WO2001093893A2 (en) 2001-12-13
DK1294390T3 (da) 2006-04-03

Similar Documents

Publication Publication Date Title
JP4328050B2 (ja) 神経保護療法のためのコポリマー1、関連ペプチド及びポリペプチドならびにそれらによって処理されたt細胞の使用
CA2398277C (en) The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for protecting cns cells from glutamate toxicity
US6835711B2 (en) Use of poly-Glu,Tyr for neuroprotective therapy
AU2002345323A1 (en) Use of poly-Glu, Tyr for neuroprotective therapy
HK1058892B (en) The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith in protecting cns cells from glutamate toxicity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051212

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090602

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090612

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120619

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4328090

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120619

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130619

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees